Business Context and Reporting Period
This Form 8-K Current Report was filed by AngioDynamics, Inc. on February 3, 2021, covering events occurring on January 29, 2021. The filing primarily addresses executive compensation arrangements rather than operational or financial performance results.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on legal agreements regarding executive severance and does not contain financial statement data.
Material Changes
On January 29, 2021, AngioDynamics entered into Amended and Restated Change in Control Agreements (CIC Agreements) with its executive leadership team, including:
- James C. Clemmer (President and CEO)
- Stephen A. Trowbridge (EVP and CFO)
- Scott Centea (SVP, Vascular Interventions and Therapies)
- David D. Helsel (SVP, Global Operations and R&D)
- Chad Thomas Campbell (SVP, Vascular Access)
These agreements effectuate changes previously approved by shareholders and described in the definitive proxy statement filed on September 3, 2020.
Guidance, Outlook, and Management Commentary
The filing details the specific severance benefits triggered if an executive is terminated without "cause" or resigns for "good reason" following a "change in control" (or within three months prior under specific conditions). Key provisions include:
- Severance Payment: A lump sum equal to 1.5 times the sum of base salary and target bonus (2 times for Mr. Clemmer).
- Bonuses: Payment of any earned but unpaid prior year bonus and a prorated bonus for the year of termination based on historical averages.
- Benefits: Cashout of unused vacation leave and an 18-month COBRA subsidy (24 months for Mr. Clemmer).
- Equity: Accelerated vesting of outstanding equity awards, with performance-based requirements deemed achieved at the "target" level.
- Conditions: Payments are contingent upon the executive signing a release of claims and a restrictive covenant agreement, including a 24-month non-compete and non-solicit.
- Term: Agreements expire annually on December 31 with automatic renewal unless 60 days' notice is given. In the event of a change in control, the term extends automatically for 24 months.
The agreements include a "best-after-tax" Section 280G cutback provision to mitigate excise taxes.
Investor Verification Checklist
- Verify the specific terms of the Change in Control Agreements by reviewing Exhibit 10.1 (Mr. Clemmer) and Exhibit 10.2 (Other Executives) attached to the filing.
- Confirm the definitions of "cause," "good reason," and "change in control" as they appear in the attached exhibits to understand the precise triggers for severance.
- Review the September 3, 2020, definitive proxy statement for the original shareholder approval context regarding these compensation arrangements.
- Note that this filing contains no financial performance data; refer to the most recent 10-Q or 10-K for revenue and earnings metrics.